Completed
For the purposes of this study, a "drug" includes prescription drugs and biologics, excluding blood and blood products and tissues for transplantation. The objectives of the study are: To develop a fuller understanding of drug safety and quality issues through the conduct of an evidence-based review of the literature, case studies and analysis. This review will consider the nature and causes of medication errors; their impact on patients; and the differences in causation, impact and prevention across multiple dimensions of health care delivery including patient populations, care settings, clinicians, and institutional cultures
Featured publication
Consensus
·2007
In 1996 the Institute of Medicine launched the Quality Chasm Series, a series of reports focused on assessing and improving the nation's quality of health care. Preventing Medication Errors is the newest volume in the series. Responding to the key messages in earlier volumes of the series—To Err Is...
View details
Description
For the purposes of this study, a "drug" includes prescription drugs and biologics, excluding blood and blood products and tissues for transplantation.The objectives of the study are: 1. To develop a fuller understanding of drug safety and quality issues through the conduct of an evidence-based review of the literature, case studies and analysis. This review will consider the nature and causes of medication errors; their impact on patients; and the differences in causation, impact and prevention across multiple dimensions of health care delivery including patient populations, care settings, clinicians, and institutional cultures. 2. If possible, to develop estimates of the incidence, severity and costs of medication errors that can be useful in prioritizing resources for national quality improvement efforts and influencing national health care policy. 3. To evaluate alternative approaches to reducing medication errors in terms of their efficacy, cost-effectiveness, appropriateness in different settings and circumstances, feasibility, institutional barriers to implementation, associated risk, and quality of evidence supporting the approach. 4. To provide guidance to consumers, providers, payers, and other key stakeholders on high-priority strategies to achieve both short-term and long-term drug safety goals, to elucidate the goals and expected results of such initiatives and support the business case for them, and to identify critical success factors and key levers for achieving success.5. To assess opportunities and key impediments to broad nationwide implementation of medication error reductions, and to provide guidance to policy-makers and government agencies in promoting a national agenda for medication error reduction. 6. To develop an applied research agenda to evaluate the health and cost impacts of alternative interventions, and to assess collaborative public and private strategies for implementing the research agenda through AHRQ and other government agencies. Sponsor: U.S. Department of Health and Human Services, Centers for Medicare and Medicaid ServicesThe approximate starting date for the project is 09/01/2004.The committee will produce one report in Spring 2006.
Collaborators
Committee
Co-Chair
Co-Chair
Member
Member
Member
Member
Member
Member
Member
Member
Member
Member
Member
Member
Member
Member
Member
Committee Membership Roster Comments
As of April 5, 2005, Dr Cannon was added to the committee. Dr. William Evans is no longer on the committee, effective March 11, 2005.
Note (02/14/2006): The bio-sketches of the following four members have been updated - Dr Califf, Dr Flynn, Mr Inlander, and Dr Wu.
Sponsors
Department of Health and Human Services
Staff
Philip Aspden
Lead
Major units and sub-units
Institute of Medicine
Lead
Board on Health Care Services
Lead